CB2 cannabinoid receptors contribute to bacterial invasion and mortality in polymicrobial sepsis

PLoS ONE

Volumn 4, Issue 7, 2009, Pages

  Csóka, Balázs ^a   Németh, Zoltán H ^a,b   Mukhopadhyay, Partha ^c   Spolarics, Zoltán ^a   Rajesh, Mohanraj ^c   Federici, Stephanie ^a   Deitch, Edwin A ^a   Bátkai, Sándor ^c   Pacher, Pál ^c   Haskó, György ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b MORRISTOWN MEMORIAL HOSPITAL   (United States)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 2 RECEPTOR; CD11B ANTIGEN; CD19 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BACTERIAL TRANSLOCATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE FUNCTION; GENE INACTIVATION; GENE REPRESSION; IMMUNE RESPONSE; KIDNEY INJURY; KNOCKOUT MOUSE; LYMPHOCYTE COUNT; LYMPHOID ORGAN; MORTALITY; MOUSE; MUSCLE INJURY; NONHUMAN; POLYMICROBIAL SEPSIS; SEPSIS; SURVIVAL TIME; WILD TYPE; ANIMAL; BACTERIAL PHENOMENA AND FUNCTIONS; C57BL MOUSE; FLOW CYTOMETRY; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY; WESTERN BLOTTING;

ANIMALIA; BACTERIA (MICROORGANISMS); MUS;

ANIMALS; BACTERIAL PHYSIOLOGICAL PHENOMENA; BLOTTING, WESTERN; CYTOKINES; FLOW CYTOMETRY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTOR, CANNABINOID, CB2; SEPSIS;

EID: 68149166272     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006409     Document Type: Article

References (54)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, et al. (2001) Epidemiology of severe sepsis in the united states: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 29(7): 1303-1310.
2. Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the united states from 1979 through 2000. N Engl J Med 348(16): 1546-1554.
3. Benjamim CF, Hogaboam CM, Kunkel SL (2004) The chronic consequences of severe sepsis. J Leukoc Biol 75(3): 408-412.
4. Oberholzer A, Oberholzer C, Moldawer LL (2001) Sepsis syndromes: Understanding the role of innate and acquired immunity. Shock 16(2): 83-96.
5. Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348(2): 138-150.
6. Riedemann NC, Guo RF, Bernacki KD, Reuben JS, Laudes IJ, et al. (2003) Regulation by C5a of neutrophil activation during sepsis. Immunity 19(2): 193-202.
7. Ayala A, Chaudry IH (1996) Immune dysfunction in murine polymicrobial sepsis: Mediators, macrophages, lymphocytes and apoptosis. Shock 6 Suppl 1: S27-38
8. Pacher P, Batkai S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58(3): 389-462.
9. Di Marzo V (2008) Targeting the endocannabinoid system: To enhance or reduce? Nat Rev Drug Discov 7(5): 438-455.
10. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, et al. (2002) International union of pharmacology. XXVII. classification of cannabinoid receptors. Pharmacol Rev 54(2): 161-202.
11. Di Marzo V, De Petrocellis L, Sepe N, Buono A (1996) Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem J 316 (Pt 3)(Pt 3): 977-984.
12. Pacher P, Hasko G (2008) Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 153(2): 252-262.
13. Matias I, Pochard P, Orlando P, Salzet M, Pestel J, et al. (2002) Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem 269(15): 3771-3778.
14. Batkai S, Osei-Hyiaman D, Pan H, El-Assal O, Rajesh M, et al. (2007) Cannabinoid-2 receptor mediates protection against hepatic ischemia/ reperfusion injury. FASEB J 21(8): 1788-1800.
15. Mukhopadhyay P, Batkai S, Rajesh M, Czifra N, Harvey-White J, et al. (2007) Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol 50(6): 528-536.
16. Wang Y, Liu Y, Ito Y, Hashiguchi T, Kitajima I, et al. (2001) Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: Increase in endogenous cannabinoids in the sera of patients with endotoxic shock. Anal Biochem 294(1): 73-82.
17. Varga K, Wagner JA, Bridgen DT, Kunos G (1998) Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12(11): 1035-1044.
18. Wagner JA, Varga K, Kunos G (1998) Cardiovascular actions of cannabinoids and their generation during shock. J Mol Med 76(12): 824-836.
19. Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, et al. (1997) Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390(6659): 518-521.
20. Wagner JA, Hu K, Bauersachs J, Karcher J, Wiesler M, et al. (2001) Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J Am Coll Cardiol 38(7): 2048-2054.
21. Klein TW (2005) Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5(5): 400-411.
22. Correa F, Mestre L, Docagne F, Guaza C (2005) Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: Role of IL-10 and ERK1/2 kinase signaling. Br J Pharmacol 145(4): 441-448.
23. McCoy KL, Matveyeva M, Carlisle SJ, Cabral GA (1999) Cannabinoid inhibition of the processing of intact lysozyme by macrophages: Evidence for CB2 receptor participation. J Pharmacol Exp Ther 289(3): 1620-1625.
24. Matveyeva M, Hartmann CB, Harrison MT, Cabral GA, McCoy KL (2000) Delta(9)-tetrahydrocannabinol selectively increases aspartyl cathepsin D proteolytic activity and impairs lysozyme processing by macrophages. Int J Immunopharmacol 22(5): 373-381.
25. Nemeth ZH, Csoka B, Wilmanski J, Xu D, Lu Q, et al. (2006) Adenosine A2A receptor inactivation increases survival in polymicrobial sepsis. J Immunol 176(9): 5616-5626.
26. Csoka B, Nemeth ZH, Selmeczy Z, Koscso B, Pacher P, et al. (2007) Role of A(2A) adenosine receptors in regulation of opsonized E. coli-induced macrophage function. Purinergic Signal 3(4): 447-452.
27. Chandra R, Villanueva E, Feketova E, Machiedo GW, Hasko G, et al. (2008) Endotoxemia down-regulates bone marrow lymphopoiesis but stimulates myelopoiesis: The effect of G6PD deficiency. J Leukoc Biol 83(6): 1541-1550.
28. Lyons A, Kelly JL, Rodrick ML, Mannick JA, Lederer JA (1997) Major injury induces increased production of interleukin-10 by cells of the immune system with a negative impact on resistance to infection. Ann Surg 226(4): 450-8; discussion 458-60.
29. Steinhauser ML, Hogaboam CM, Kunkel SL, Lukacs NW, Strieter RM, et al. (1999) IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol 162(1): 392-399.
30. Song GY, Chung CS, Chaudry IH, Ayala A (2000) Immune suppression in polymicrobial sepsis: Differential regulation of Th1 and Th2 responses by p38 MAPK. J Surg Res 91(2): 141-146.
31. Kalechman Y, Gafter U, Gal R, Rushkin G, Yan D, et al. (2002) Anti-IL-10 therapeutic strategy using the immunomodulator AS101 in protecting mice from sepsis-induced death: Dependence on timing of immunomodulating intervention. J Immunol 169(1): 384-392.
32. Riedemann NC, Neff TA, Guo RF, Bernacki KD, Laudes IJ, et al. (2003) Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol 170(1): 503-507.
33. Hotchkiss RS, Chang KC, Grayson MH, Tinsley KW, Dunne BS, et al. (2003) Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves survival in sepsis. Proc Natl Acad Sci U S A 100(11): 6724-6729.
34. Hotchkiss RS, Swanson PE, Cobb JP, Jacobson A, Buchman TG, et al. (1997) Apoptosis in lymphoid and parenchymal cells during sepsis: Findings in normal and T- and B-cell-deficient mice. Crit Care Med 25(8): 1298-1307.
35. Shelley O, Murphy T, Paterson H, Mannick JA, Lederer JA (2003) Interaction between the innate and adaptive immune systems is required to survive sepsis and control inflammation after injury. Shock 20(2): 123-129.
36. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, et al. (2000) Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 396(2-3): 141-149.
37. Hasko G, Cronstein BN (2004) Adenosine: An endogenous regulator of innate immunity. Trends Immunol 25(1): 33-39.
38. Hasko G, Linden J, Cronstein B, Pacher P (2008) Adenosine receptors: Therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7(9): 759-770.
39. Enoh VT, Fairchild CD, Lin CY, Varma TK, Sherwood ER (2006) Differential effect of imipenem treatment on wild-type and NK cell-deficient CD8 knockout mice during acute intra-abdominal injury. Am J Physiol Regul Integr Comp Physiol 290(3): R685-93.
40. Enoh VT, Lin CY, Varma TK, Sherwood ER (2006) Differential effect of imipenem treatment on injury caused by cecal ligation and puncture in wild-type and NK cell-deficient beta(2)-microgloblin knockout mice. Am J Physiol Gastrointest Liver Physiol 290(2): G277-84.
41. Leibovici L, Drucker M, Konigsberger H, Samra Z, Harrari S, et al. (1997) Septic shock in bacteremic patients: Risk factors, features and prognosis. Scand J Infect Dis 29(1): 71-75.
42. Oberholzer A, Oberholzer C, Moldawer LL (2002) Interleukin-10: A complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med 30(1 Supp): S58-S63.
43. Zhu LX, Sharma S, Stolina M, Gardner B, Roth MD, et al. (2000) Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 165(1): 373-380.
44. Chung CS, Xu YX, Wang W, Chaudry IH, Ayala A (1998) Is fas ligand or endotoxin responsible for mucosal lymphocyte apoptosis in sepsis? Arch Surg 133(11): 1213-1220.
45. Hotchkiss RS, Tinsley KW, Swanson PE, Chang KC, Cobb JP, et al. (1999) Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci U S A 96(25): 14541-14546.
46. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE Jr, Hui JJ, et al. (2001) Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 166(11): 6952-6963.
47. Lombard C, Nagarkatti M, Nagarkatti P (2007) CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: Potential role for CB2-selective ligands as immunosuppressive agents. Clin Immunol 122(3): 259-270.
48. Rieder SA, Chauhan A, Singh U, Nagarkatti M, Nagarkatti P (2009) Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology.
49. Jia W, Hegde VL, Singh NP, Sisco D, Grant S, et al. (2006) Delta9-tetrahydrocannabinol-induced apoptosis in jurkat leukemia T cells is regulated by translocation of bad to mitochondria. Mol Cancer Res 4(8): 549-562.
50. McKallip RJ, Jia W, Schlomer J, Warren JW, Nagarkatti PS, et al. (2006) Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Mol Pharmacol 70(3): 897-908.
51. McKallip RJ, Lombard C, Martin BR, Nagarkatti M, Nagarkatti PS (2002) Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J Pharmacol Exp Ther 302(2): 451-465.
52. Do Y, McKallip RJ, Nagarkatti M, Nagarkatti PS (2004) Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: Novel role for endogenous and exogenous cannabinoids in immunoregulation. J Immunol 173(4): 2373-2382.
53. Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, et al. (2007) Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 13(4): 492-497.
54. Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, et al. (2007) Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 316(5830): 1494-1497.